Approach

Summary

Licensing status

Publication and contact information

Assays & screens

Cancer personalized profiling by deep sequencing (CAPP-seq) to characterize cancer using blood samples

Detection, quantification and analysis of circulating tumor DNA using CAPP-seq could help diagnose cancer and monitor response to therapy. CAPP-seq quantifies and identifies known mutations in circulating tumor DNA. In tumor samples from 13 patients with non-small cell lung cancer (NSCLC) and samples from 5 healthy controls, CAPP-seq detected cancer with 96% specificity, and quantification of plasma circulating tumor DNA levels correlated with tumor volume. In repeated sampling of three patients throughout treatment, circulating tumor DNA quantity correlated with tumor volume and better predicted residual disease and recurrence than imaging. Next steps could include validating the method in additional patients.

SciBX 7(19); doi:10.1038/scibx.2014.566
Published online May 15, 2014

Patent and licensing status unavailable

Newman, A.M. et al. Nat. Med.; published online April 6, 2014;
doi:10.1038/nm.3519
Contact: Maximilian Diehn, Stanford University, Stanford, Calif.
e-mail:

diehn@stanford.edu